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Basic haematologic parameters and serum gamma-glutamyl-transferase (GGT) activity were evaluated in a 
five-year prospective follow-up study of 25 patients with newly diagnosed epilepsy starting treatment with 
carbamazepine. In addition, we evaluated the effects of replacing carbamazepine by oxcarbazepine on these 
parameters, erythrocyte folate concentrations and serum vitamin B i2 levels in 12 male patients with epilepsy. 
The mean white blood cell count (WBC) and red blood cell count decreased after 2 months carbamazepine 
therapy, and remained at this lower level during the first 5 years of medication. The mean erythrocyte volume 
(MCV) and the serum GGT activity increased progressively during carbamazepine treatment. 
The serum GGT activity decreased after replacing carbamazepine by oxcarbazepine indicating a normalization of 
the liver P450 enzyme system induction. Concomitantly, the erythrocyte folate concentrations and serum levels of 
vitamin B,* increased, and the WBC increased and MCV decreased. 
It is probable that the changes in folate metabolism and serum vitamin B,, concentrations are due to 
normalization of the liver P450 enzyme system induction after the change of medication. The haematologic changes 
during carbamazepine medication, and their normalization after replacing carbamazepine by oxcarbazepine are 
possibly related to changes in folate and vitamin B,2 metabolism. 
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INTRODUCTION 
The use of carbamazepine, a first-line antiepilep- 
tic drug in most cases of adult-onset epilepsy, is 
associated with haematologic changes including 
mild leukopenia, decreased red blood cell count 
and blood haemoglobin concentrations, and 
enlargement of the red blood cells without 
anaemia’-‘. However, severe hematologic side- 
effects such as aplastic anaemia and agranulocy- 
tosis are rare5v8. 
The life-threatening haematologic side-effects 
of carbamazepine are caused by allergic or toxic 
mechanisms*, but the mechanisms of 
carbamazepine-induced leukopenia and macro- 
cytosis are unknown. Folate deficiency has been 
described in association with the use of many 
anticonvulsant drugs with liver enzyme inducing 
properties l”-i4. Folate is necessary for the normal 
maturation of both red and white blood cells15S’6, 
and, therefore, it seems possible that liver enzyme 
induction and the resulting folate deficiency 
could be responsible for the haematologic 
changes during carbamazepine medication. 
Oxcarbazepine, a keto-derivative of car- 
bamazepine, is a novel anticonvulsant drug which 
structurally closely resembles carbamazepine. 
The two drugs appear to have comparable 
anticonvulsant efficacy, and oxcarbazepine 
seems to be at least as well tolerated as 
carbamazepine’7Y’8. However, oxcarbazepine 
does not have the liver enzyme inducing pro- 
perties of carbamazepine’g*20. 
In this study we first evaluated basic haematol- 
ogic parameters and liver enzyme induction 
during the first 5 years of carbamazepine medica- 
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tion in patients with newly diagnosed epilepsy. 
Thereafter, the changes in haematologic indices, 
folate concentrations in erythrocytes, serum vita- 
min B,* levels, and serum gamma-glutamyl- 
transferase (GGT) activity were measured in 
male patients with epilepsy after replacing carba- 
mazepine with oxcarbazepine. 
PATIENTS AND METHODS 
The study was carried out at the Outpatient 
Department of Neurology in the University 
Hospital of Oulu with the approval of the Ethics 
committee of the Medical Faculty of the Univers- 
ity of Oulu. The principles of the Declaration of 
Helsinki were followed. Informed consent was 
obtained from all patients. The type of epilepsy 
was classified according to the International 
League Against Epilepsy (ILAE) classification*‘. 
Patients beginning carbamazepine treatment 
Altogether 25 consecutive patients with recently 
diagnosed idiopathic/cryptogenic epilepsy with- 
out prior medication participated in the study 
after giving their informed consent. They had all 
suffered at least two partial or tonic-clonic 
seizures during the previous year before the 
medication was started. The use of any other 
regular medication, alcohol abuse, pregnancy, 
lactation, or any disease possibly interfering with 
the evaluation of haematologic or liver enzyme 
parameters were regarded as exclusion criteria. 
There were 12 female patients with a mean (&sd) 
age of 35.7 f 14.4 years, and 13 male patients with 
a mean (&sd) age of 30.7 f 13.3 years at the 
beginning of the study. Fourteen patients suffered 
from generalized epilepsy, and 11 patients from 
localization related epilepsy. The seizure control 
was good in most cases after carbamazepine 
medication had been set at the therapeutic serum 
level. 
The mean carbamazepine dose was 525 f 
79mg and the mean serum carbamazepine 
concentration was 27.4 f 6.1 pmol/l after 2 
months medication, 517 f 87 mg and 26.3 f 
5.4 pmol/l after 1 year, and 568 f 187 mg and 
26.5 f 6.0 pmol/l after 5 years, respectively. 
The patients were studied before medication, 
and 2 months, 1 year, and 5 years after 
carbamazepine was started. After clinical ex- 
amination blood samples were drawn for the 
evaluation of haematologic parameters and 
gamma-glutamyl-transferase (GGT) activity at 
8.30 a.m. after an overnight fast. 
Patients changing from carbamazepine to 
oxcarbazepine 
Twelve randomly-selected male patients with 
epilepsy visiting the Outpatient Department of 
Neurology participated in this part of the study. 
The mean age of these patients was 29 years 
(range, 21-40 years). Eleven patients suffered 
from idiopathic/cryptogenic epilepsy and one 
from symptomatic epilepsy after a CNS infection 
in infancy. Six patients had generalized epilepsy, 
and six patients had localization related epilepsy. 
All patients were initially receiving car- 
bamazepine monotherapy. The daily dose of the 
medication has been unaltered for at least 1 year 
before the study. The mean duration of car- 
bamazepine medication was 8.9 years (range, 
3.5-15 years), the mean daily dose of car- 
bamazepine was 571 f 136 mg, and the mean 
serum concentration was 25.7 f 6.2 gmol/l. The 
seizure control was good in all cases during 
carbamazepine medication: 7 patients were com- 
pletely seizure free, and 5 experienced a few 
annual seizures despite the medication. None of 
the patients showed any symptoms or signs of 
diseases other than epilepsy, and none used any 
regular medication other than carbamazepine. 
The mean daily oxcarbazepine dose was 
913 f 251 mg and the mean serum concentration 
of 10, 11-dihydro-lo-hydroxy-carbamazepine, the 
main active metabolite of oxcarbazepine, was 
35.9 f 8.7 kmol/l after 2 months’ oxcarbazepine 
medication, and lOOOk 322mg and 43.1 f 
12.9 pmol/l after 6 months’ medication, 
respectively. 
The patients were studied three times. At the 
first visit they were on carbamazepine medica- 
tion. After the blood samples had been taken, 
carbamazepine medication was replaced by an 
equivalent daily dose of oxcarbazepine, i.e. the 
daily oxcarbazepine dose was 1.5-fold compared 
with the daily dose of carbamazepine”. If the 
patients experienced seizures during oxcar- 
bazepine medication, the dose was increased. The 
second and third examinations were made 2 and 6 
months after the switch from carbamazepine to 
oxcarbazepine. 
During every visit a clinical examination was 
done, and thereafter blood samples were ob- 
tained for the measurement of the haematologic 
parameters, serum GGT activity, and the erythr- 
ocyte folate and serum vitamin B,, concentrations 
at 8.30 a.m. after an overnight fast. 
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Assays 
The basic haematologic laboratory parameters 
(white blood cell count, WBC; red blood cell 
count, RBC, erythrocyte volume = mean corpus- 
cular volume, MCV; haemoglobin concentration 
and haematocrit) were measured using the 
Coulter Counter Model S-Plus analyser (Coulter 
Electronics Ltd., Luton, England). Serum GGT 
activities were determined according to the 
recommendations of the European Committee 
for Clinical Laboratory Standards22 in order to 
evaluate liver enzyme induction23. Erythrocyte 
folate concentrations were assayed using reagent 
kits from Bio-Rad Clinical Division (Richmond, 
Ca.). Serum vitamin B,2 concentrations were 
assayed using the Ciba Corning Automated 
Chemiluminescence System (ACS) (Ciba Corn- 
ing Corp., Medfield, Ma.). The analyses were 
performed according to the instructions of the 
manufacturer. 
Statistics 
The statistical analysis of the results was 
performed using analysis of variance (ANOVA) 
for repeated measures and Fisher’s lsd test. 
RESULTS 
The results are presented in Tables 1 and 2. The 
mean WBC decreased after 2 months’ car- 
bamazepine treatment and remained at this lower 
level during the first 5 years of medication (Table 
1). Furthermore, a slight decrease was found in 
the mean red blood cell count (RBC) after 2 
months carbamazepine treatment and thereafter. 
The decrease in mean blood haemoglobin con- 
centration was transient during the first 12 
months of carbamazepine medication. The MCV 
increased gradually and progressively during the 
years of carbamazepine treatment, and the 
increase was statistically significant after 5 years 
(P <O.OOl). A progressive increase of serum 
GGT activities was also found during the first 5 
years of carbamazepine medication. 
The mean WBC increased 2 months after 
replacing carbamazepine by oxcarbazepine and it 
was still higher after 6 months (Table 2). The 
MCV decreased, but the mean RBC, haemog- 
lobin concentration, and the haematocrit remained 
unaltered after the medication was changed. 
Serum GGT activities decreased, and the erythr- 
ocyte folate levels increased after 2 months and 
showed a further increase after 6 months oxcar- 
bazepine medication. The concentrations of 
serum vitamin B,2 increased after 6 months. 
DISCUSSION 
The mean WBC decreased after 2 months’ 
carbamazepine medication, and remained at this 
lower level quite constantly during the next 5 
years. The MCV and serum GGT activities 
increased progressively during the 5 years. 
Replacing carbamazepine by oxcarbazepine re- 
suited’ in a decrease in serum GGT activities 
indicating a normalization of liver enzyme 
induction. Furthermore, a concomitant increase 
in erythrocyte folate levels and serum vitamin B,2 
concentrations was observed, and the WBC 
increased and the MCV decreased after the 
change in the medication. 
The decreased mean WBC, the slight transient 
decrease of serum haemoglobin, as well as the 
decreased RBC during carbamazepine medica- 
tion are in accordance with the previous 
literature1’3*“*6-8.24. The progressive increase of the 
size of the erythrocytes during the first 5 years of 
carbamazepine medication has not been reported 
earlier, although an increase after 2 years was 
Table 1: The basic haematologic laboratory results and serum gamma-glutamyl-transferase (GGT) activities in patients with 
epilepsy (n = 25) starting treatment with carbamazepine. Values are means f sd 
Before After 2 After 1 After 5 
medication months year years 
WBC (xlO’/l) 7.5 f  2.3 5.8 f  1.8*** 6.0 f  1.6*** 5.6 f  1.6*** 
RBC (xlO”/l) 4.7 f  0.3 4.5 l 0.4** 4.5 f  0.5** 4.5 f  0.4*** 
MCV (fl) 88.0 f  6.1 88.2 f  6.0 88.7 f  4.5 92.8 f  3.8*** 
Hb (g/l) 142.2 f  13.5 138.1 f  ll.l** 138.1 f  12.3** 142.3 f  12.1 
Her 0.41 f  0.04 0.40 f  0.03* 0.40 f  0.04 0.42 f  0.04 
GGT (U/l) 16.3 f  12.2 44.4 f  42.1** 58.4 f  62.0*** 86 . 8 f  62 . 9*** 
WBC, white blood cell count; RBC red blood cell count; MCV, mean corpuscular volume: Hb, haemoglobin; Her, haematocrit; 
GGT, gamma-glutamyl-transferase *P < 0.05, **P < 0.01, ***P < 0.001; ANOVA for repeated measures and Fisher’s Isd test, 
compared with the values before medication. 
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Table 2: The basic haematologic laboratory results, serum gamma-glutamyl-transferase (GGT) activities, erythrocyte folate 
levels, and serum vitamin B,, concentrations in patients with epilepsy (n = 12) during carbamazepine and the following 
oxcarbazepine medication. Values are means f sd 
Medication 
Carbamazepine 
2 months 
Oxcarbazepine 
6 months 
WBC (X109/1) 
RBC (x1012/l) 
MCV (fl) 
Hb k/U 
Her 
GGT (p/l) 
E-folate (nmol/l) 
Vitamin B,, (pmol/l) 
5.1 f  1.0 
4.8 f  0.3 
94.0 f  2.4 
151.7 f  7.2 
0.45 f  0.02 
65.1 f  41.2 
369.4 f  56.4 
450.5 f  133.3 
5.8 f  1.3** 
4.7 f  0.3 
92.9 f  2.7* 
150.5 f  8.7 
0.44 * 0.03 
38.8 i 15.6*** 
417.8 f  64.6** 
445.0 f  88.7 
6.4 f  1.5*** 
4.9 f  0.4 
92.7 f  3.5* 
152.8 f  7.4 
0.45 f  0.02 
39.5 f  21.2*** 
466.9 f  73.2*** 
497.8 f  123.5* 
Abbreviations as in Table 1. 
*P < 0.05, **P < 0.01, ***P < 0.001; ANOVA for repeated measures and Fisher’s Isd test, compared with the values during 
carbamazepine medication. 
foundg. The changes in serum GGT activities, 
erythrocyte folate and serum vitamin B12 levels, 
and haematologic parameters after replacing car- 
bamazepine with oxcarbazepine are new findings. 
Serum GGT activities increased progressively 
during the 5 years of carbamazepine medication 
and this phenomenon is probably associated 
with liver enzyme induction caused by 
carbamazepine23. On the other hand serum GGT 
activities decreased after substituting oxcar- 
bazepine for carbamazepine indicating a nor- 
malization of liver enzyme induction. Further- 
more, it has also been shown previously by 
measuring antipyrine kinetics that the induction 
of the liver P450 enzyme system is normalized 
after changing the medication from car- 
bamazepine to oxcarbazepine”. 
Folate deficiency has been described in as- 
sociation with the use of many anticonvulsant 
drugs with liver enzyme inducing properties’&“, 
although the decrease was not statistically sig- 
nificant in a short-term prospective study during 
carbamazepine medication25. It has been sug- 
gested that the enzymes involved in folate 
metabolism may be induced or the demand for 
folic acid as a coenzyme in drug-induced enzyme 
reactions may be increased during the use of liver 
enzyme inducing antiepileptic drugs137’4. Folate is 
necessary for the normal maturation of both red 
and white blood cells, and folate deficiency can 
lead to macrocytosis of the red blood cells, and to 
leukopeniai5v16. Therefore, folate deficiency could 
lead to maturation defects in red and white blood 
cells and to the development of macrocytosis and 
leukopenia during carbamazepine treatment. In 
the present study folate concentrations were not 
analysed in the patients starting treatment with 
carbamazepine, but the concomitant increase in 
erythrocyte folate levels with the increase in the 
WBC and decrease in the size of the erythrocytes 
after replacing carbamazepine with oxcar- 
bazepine supports this hypothesis. It is also 
possible that vitamin Bi2 has some role in these 
changes. The decreased concentrations of serum 
vitamin Bi2 could contribute to the decrease in 
folate concentrations together with the direct 
effects of the medication on folate metabolism 
via liver enzyme induction. 
The increased size of the erythrocytes was not 
associated with anaemia during carbamazepine 
medication, and, therefore, did not indicate a 
clinically significant disturbance of erythrocyte 
maturation. However, it seems that the underly- 
ing difference between the metabolic effects of 
carbamazepine and oxcarbazepine may be more 
important than the resulting mild haematologic 
changes. The different effects of carbamazepine 
and oxcarbazepine on folate metabolism could 
have certain clinical implications. It has been 
reported that the occurrence of developmental 
abnormalities in the infants of epileptic mothers 
can be associated with low serum folate levels 
during pregnancy2’j, and, therefore, the use of 
oxcarbazepine instead of carbamazepine may be 
preferred in young women with epilepsy. 
In conclusion, the results of the present study 
show that the mild changes in haematologic 
indices during carbamazepine medication are 
normalized after replacing carbamazepine with 
oxcarbazepine. The underlying mechanism is 
probably the concomitant increase in erythrocyte 
folate levels and serum vitamin Bi2 concentra- 
tions, which results from the normalization of 
liver P450 enzyme system induction. 
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